EPS for Array BioPharma Inc. (ARRY) forecasted at $-0.21

April 17, 2018 - By Sheila Anderson

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo
Big Money Sentiment increased to 1.3 in 2017 Q4. It has change of 0.09, from 2017Q3’s 1.21. The ratio is positive due to Array BioPharma Inc. positioning: 20 sold and 50 reduced. 27 funds took stakes and 64 increased stakes. Investors holded 190.80 million in 2017Q3 but now own 194.11 million shares or 1.73% more.
Us Fincl Bank De reported 490 shs. Pinnacle reported 0.67% stake. Jane Street Limited Liability Corp accumulated 0% or 69,806 shs. Geode Capital Mngmt Ltd owns 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 1.87 million shs. Aperio Gru Lc has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). First Mercantile Tru reported 14,222 shs stake. Cambiar Ltd has invested 0.1% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). Fin And Investment Mgmt Gp Ltd holds 220,806 shs. Goldman Sachs Grp invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Moreover, Jpmorgan Chase & Company has 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 46,475 shs. Rhumbline Advisers has 0.01% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 192,811 shs. Morgan Stanley invested in 3.68 million shs or 0.01% of the stock. Moreover, Polar Capital Limited Liability Partnership has 0.03% invested in Array BioPharma Inc. (NASDAQ:ARRY). Putnam Limited, Massachusetts-based fund reported 300,028 shs. 151,241 were accumulated by Manufacturers Life Insur The.

Array BioPharma Inc. had 8 insider sales and 0 insider purchases since December 16, 2017. This’s net activity of $15.94 million. $8.90 million worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by Squarer Ron. $360,340 worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by VAN LUNSEN GIL J on Wednesday, March 21. 7,500 shs were sold by Haddock Jason, worth $102,975 on Tuesday, January 16. Robbins Andrew R also sold $3.03M worth of Array BioPharma Inc. (NASDAQ:ARRY) on Saturday, December 16.

Investors expect Array BioPharma Inc. (NASDAQ:ARRY)’s quarterly earnings on May, 9., Zacks reports. Analysts expect change of 0.00 % or $0.00 from previous year’s $-0.21 earnings per share compared to current’s $-0.21 earnings per share. After $-0.17 earnings per share was announced last quarter, analysts now see negative EPS growth of 23.53 % for Array BioPharma Inc.. ARRY reached $15.02 on during the last trading session after $0.14 change.Currently Array BioPharma Inc. is uptrending after 68.58% change in last April 17, 2017. ARRY has also 1.10 million shares volume. ARRY outperformed the S&P500 by 57.03%.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

In total 5 analysts cover Array Biopharma (NASDAQ:ARRY). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 13 are the (NASDAQ:ARRY)’s analyst reports since October 31, 2017 according to StockzIntelligence Inc. On Sunday, January 21 the rating was maintained by Cowen & Co with “Buy”. On Tuesday, October 31 the rating was maintained by Piper Jaffray with “Buy”. On Tuesday, October 31 the rating was maintained by Stifel Nicolaus with “Buy”. In Tuesday, October 31 report SunTrust maintained it with “Buy” rating and $16.0 target. On Tuesday, February 6 SunTrust maintained Array BioPharma Inc. (NASDAQ:ARRY) rating. SunTrust has “Buy” rating and $20.0 target. In Wednesday, November 29 report Piper Jaffray maintained the stock with “Buy” rating. On Monday, January 22 the stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Outperform” rating by Leerink Swann. The stock rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, February 6. On Wednesday, February 7 the stock has “Buy” rating by Cowen & Co. In Tuesday, February 6 report Piper Jaffray maintained the stock with “Buy” rating.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The firm is worth $3.12 billion. The company??s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Last it reported negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.